|
|
Article: New Assay Detects 100 Percent of Stage I, II and III Colon Cancers in Pre-Clinical Trials.
- Article from:
- Cancer Weekly
- Article date:
- September 29, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Marking a major milestone in the early detection and management of colon cancer, EDP Biotech Corporation (EDP), a developer of immunodiagnostic tests for humans and animals, announced that its ColoMarker™ assay achieved 100 percent detection rate for colon cancers presented at stages I through III in pre-clinical trials. ColoMarker is the first assay of its kind to enable both early detection screening and patient management capabilities, presenting the potential to save time, money and, most importantly, lives (see also Colon Cancer).
"ColoMarker could radically change the way we detect and treat colon cancer," said Kevin Jones, Ph.D., Chief Scientific ...